Safety study of leucoreduced allogeneic pooled freeze-dried platelet-rich plasma in healthy equine joints.
Abstract: Clinical use of blood-derived intra-articular therapies, such as platelet-rich plasma (PRP), have increased in equine athletes due to their proposed disease-modifying effects. Need for a shelf-stable, allogeneic PRP product with known composition for standardized treatment exists. The objective of this study was to compare systemic and local effects of a single intra-articular injection of equine leucoreduced allogeneic pooled freeze-dried PRP (alloPRP) to a placebo control (saline) in normal, healthy equine joints. Unassigned: Twelve healthy horses were randomly assigned to either control (saline) or treatment (alloPRP) ( = 6 horses per group). The study used a blinded 2-period, 2-treatment, 2-joint non-crossover experimental design. Each study period was defined as 1 week, followed by a 2-week washout between study periods. One joint (radiocarpal or tarsocrural joint) was treated and evaluated per study period. Treatment sequence and limbs chosen for treatment were randomized for each horse. Systemic effects were measured at different time points by physical examination, bloodwork (complete blood count and serum biochemistry), and lameness examination (subjective and objective). Local effects to the joint measured at different time points included heat, swelling, joint circumference, and response to passive flexion as well as synovial fluid analysis. Data was analyzed using linear mixed models with significance set at < 0.05. Unassigned: There were no differences between groups for joint swelling ( = 0.40), joint circumference ( = 0.55), heat scores ( = 0.09), or passive flexion ( 0.70) following intra-articular injections. Both subjective and objective lameness scores were no different on any study day for both treatment ( 0.47) and control groups ( 0.31). There were no differences in complete blood count or serum biochemistry values between groups. No difference in synovial fluid TNCC ( = 0.80), TP ( = 0.94), or synovial fluid concentrations of TNFα ( 0.45) and IL-1raP ( 0.18) were observed between groups for each sampled time point (T0 and T7d). Unassigned: The alloPRP formulation was demonstrated to be safe for use in equine joints. Further investigation is necessary for evaluation of clinical efficacy.
Copyright © 2025 Kooy, Constant, Cole and Boone.
Publication Date: 2025-07-14 PubMed ID: 40727274PubMed Central: PMC12301550DOI: 10.3389/fvets.2025.1625431Google Scholar: Lookup
The Equine Research Bank provides access to a large database of publicly available scientific literature. Inclusion in the Research Bank does not imply endorsement of study methods or findings by Mad Barn.
- Journal Article
Summary
This research summary has been generated with artificial intelligence and may contain errors and omissions. Refer to the original study to confirm details provided. Submit correction.
The research examines the safety of using leucoreduced allogeneic pooled freeze-dried platelet-rich plasma (alloPRP) in horse joints, comparing its effects with saline as a control. The results indicate that the alloPRP formulation is safe for use, but its clinical effectiveness needs further exploration.
Study Objective and Methodology
- The primary objective of this research was to assess the systemic and local effects of an injection of equine leucoreduced allogeneic pooled freeze-dried PRP (alloPRP) compared to a placebo control (saline) in healthy horse joints.
- The researchers used a double-blind non-crossover experimental design involving a total of 12 healthy horses. These animals were randomly split into two groups (6 per group) with the first group receiving the alloPRP treatment and the other being administered a control saline solution.
- The study was carried out over two periods of one week each, segregated by a two-week ‘washout’ period. In each period, a joint (either the radiocarpal or tarsocrural joint) was treated and evaluated.
Measurements and Data Analysis
- Both systemic and local effects were measured at various time points, using physical examination, complete blood count, serum biochemistry, and both subjective and objective lameness examinations.
- Local effects on the joint were also measured, which included heat, swelling, joint circumference, synovial fluid analysis, and the response to passive flexion.
- The gathered data was analyzed using linear mixed models and the level of significance set at <0.05.
Results
- Results demonstrated no significant differences between the alloPRP treatment group and the control group in terms of joint swelling, joint circumference, heat scores, passive flexion, or lameness scores on any study day.
- Additionally, there were no observed differences in complete blood count or serum biochemistry values between the groups.
- Even synovial fluid analyses—specifically TNCC, TP, TNFα, and IL-1raP concentrations—showed no distinction between the groups at sampled time points.
Conclusion
- The study concluded that the use of alloPRP was safe in equine joints, despite not showing significant differences when compared to a saline solution.
- However, the team juxtaposed this result with an acknowledgment that further study is needed to evaluate the clinical efficacy of alloPRP treatments.
Cite This Article
APA
Kooy S, Constant J, Cole R, Boone L.
(2025).
Safety study of leucoreduced allogeneic pooled freeze-dried platelet-rich plasma in healthy equine joints.
Front Vet Sci, 12, 1625431.
https://doi.org/10.3389/fvets.2025.1625431 Publication
Researcher Affiliations
- Department of Clinical Sciences, College of Veterinary Medicine, Auburn University, Auburn, AL, United States.
- College of Veterinary Medicine, Auburn University, Auburn, AL, United States.
- Department of Clinical Sciences, College of Veterinary Medicine, Auburn University, Auburn, AL, United States.
- Department of Clinical Sciences, College of Veterinary Medicine, Auburn University, Auburn, AL, United States.
Conflict of Interest Statement
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
References
This article includes 25 references
- Ireland JL, Clegg PD, McGowan CM, McKane SA, Chandler KJ, Pinchbeck GL. Disease prevalence in geriatric horses in the United Kingdom: veterinary clinical assessment of 200 cases.. Equine Vet J (2012) 44:101–6.
- Caron JP, Genovese RL. Principles and practices of joint disease treatment. In: Diagnosis and management of lameness in the horse. eds. Ross, M and Sue Dyson, S USA: Elsevier science. (2003). 746–64.
- Bogers SH. Cell-based therapies for joint disease in veterinary medicine: what we have learned and what we need to know.. Front Vet Sci (2018) 5:70.
- Peng C, Yang L, Labens R, Gao Y, Zhu Y, Li J. A systematic review and Meta-analysis of the efficacy of platelet-rich plasma products for treatment of equine joint disease.. Equine Vet J (2024) 56:858–69.
- Tokawa PKA, Baccarin RYA, Zanotto GM. Intra-articular corticosteroids: systematic review of effects on osteoarthritis and joint health.. Equine Vet Educ (2025) 37:371–81.
- Ríos DL, López C, Carmona JU. Platelet-rich gel supernatants stimulate the release of anti-inflammatory proteins on culture Media of Normal Equine Synovial Membrane Explants.. Vet Med Int (2015) 2015:547052: 1–9.
- Carmona JU, Ríos DL, López C, Álvarez ME, Pérez JE, Bohórquez ME. effects of platelet-rich gel supernatants on histology and chondrocyte apoptosis scores, hyaluronan release and gene expression of equine cartilage explants challenged with lipopolysaccharide.. BMC Vet Res (2016) 12:135.
- Hosseini S, Soltani-Zangbar MS, Zamani M, Yaghoubi Y, Rikhtegar Ghiasi R, Motavalli R. Comparative evaluation of autologous platelet-rich plasma and platelet lysate in patients with knee osteoarthritis.. Growth Factors (2023) 41:165–77.
- Peña AN, Sommerfeld SD, Anderson AE, Han J, Maestas DR, Mejias JC. Autologous protein solution processing alters lymphoid and myeloid cell populations and modulates gene expression dependent on cell type.. Arthritis Res Ther (2022) 24:221.
- Tyrnenopoulou P, Diakakis N, Karayannopoulou M, Savvas I, Koliakos G. Evaluation of intra-articular injection of autologous platelet lysate (Pl) in horses with osteoarthritis of the distal interphalangeal joint.. Vet Q (2016) 36:56–62.
- Garbin LC, Contino EK, Olver CS, Frisbie DD. A safety evaluation of allogeneic freeze-dried platelet-rich plasma or conditioned serum compared to autologous frozen products equivalents in equine healthy joints.. BMC Vet Res (2022) 18:141.
- Camargo Garbin L, McIlwraith CW, Frisbie DD. Evaluation of allogeneic freeze-dried platelet lysate in cartilage exposed to interleukin 1-Β .. BMC Vet Res (2019) 15:386.
- Pietramaggiori G, Scherer SS, Mathews JC, Alperovich M, Yang HJ, Neuwalder J. Healing modulation induced by freeze-dried platelet-rich plasma and micronized allogeneic dermis in a diabetic wound model.. Wound Repair Regen (2008) 16:218–25.
- McCarrel T, Fortier L. Temporal growth factor release from platelet-rich plasma, Trehalose lyophilized platelets, and bone marrow aspirate and their effect on tendon and ligament gene expression.. J Orthop Res (2009) 27:1033–42.
- Hassan NH, Ahmad RE, Kamarul T, Looi QHD, Chong PP. Allogenic platelet-rich plasma for treating cartilage injury: a systematic review of the evidence on the basic sciences for potential future applications.. Cells Tissues Organs (2024) 213:338–55.
- Zhang ZY, Huang AW, Fan JJ, Wei K, Jin D, Chen B. The potential use of allogeneic platelet-rich plasma for large bone defect treatment: immunogenicity and defect healing efficacy.. Cell Transplant (2013) 22:175–87.
- Jo CH, Lee SY, Yoon KS, Oh S, Shin S. Allogenic pure platelet-rich plasma therapy for rotator cuff disease: a bench and bed study.. Am J Sports Med (2018) 46:3142–54.
- Textor JA, Tablin F. Intra-articular use of a platelet-rich product in Normal horses: clinical signs and Cytologic responses.. Vet Surg (2013) 42:499–510.
- Moreira JJ, Moraes APL, Brossi PM, Machado TS, Michelacci YM, Massoco CO. Autologous processed plasma: cytokine profile and effects upon injection into healthy equine joints.. J Vet Sci (2015) 16:47.
- Smit Y, Thompson PN, Mahne AT, Marais HJ, Goddard A. Clinical findings, synovial fluid cytology and growth factor concentrations after intra-articular use of a platelet-rich product in horses with osteoarthritis.. J S Afr Vet Assoc (2019) 90:1–9.
- Velloso Alvarez A, Boone LH, Braim AP, Taintor JS, Caldwell F, Wright JC. A survey of clinical usage of non-steroidal intra-articular therapeutics by equine practitioners.. Front Vet Sci (2020) 7:579967.
- Owens SD, Kol A, Walker NJ, Borjesson DL. Allogeneic mesenchymal stem cell treatment induces specific alloantibodies in horses.. Stem Cells Int (2016) 2016:1–8.
- Colbath AC, Dow SW, Hopkins LS, Phillips JN, McIlwraith CW, Goodrich LR. Allogeneic vs. autologous intra-articular mesenchymal stem cell injection within normal horses: clinical and cytological comparisons suggest safety.. Equine Vet J (2020) 52:144–51.
- Colbath AC, Dow SW, Hopkins LS, Phillips JN, McIlwraith CW, Goodrich LR. Induction of synovitis using interleukin-1 beta: are there differences in the response of middle carpal joint compared to the tibiotarsal joint?. Front Vet Sci (2018) 5:208.
- Moraes APL, Moreira JJ, Brossi PM, Machado TS, Michelacci YM, Baccarin RY. Short- and long-term effects of platelet-rich plasma upon healthy equine joints: clinical and laboratory aspects.. Can Vet J (2015) 56:831.
Citations
This article has been cited 0 times.Use Nutrition Calculator
Check if your horse's diet meets their nutrition requirements with our easy-to-use tool Check your horse's diet with our easy-to-use tool
Talk to a Nutritionist
Discuss your horse's feeding plan with our experts over a free phone consultation Discuss your horse's diet over a phone consultation
Submit Diet Evaluation
Get a customized feeding plan for your horse formulated by our equine nutritionists Get a custom feeding plan formulated by our nutritionists
